×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ABUS – arbutus biopharma corporation (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ABUS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/4
05:00 pm
abus
Why Moderna (MRNA) Stock Is Trading Up Today [Yahoo! Finance]
Neutral
Report
Why Moderna (MRNA) Stock Is Trading Up Today [Yahoo! Finance]
3/4
10:13 am
abus
Moderna Stock Pops After Inking $950 Million Covid Vaccine Settlement [Yahoo! Finance]
Medium
Report
Moderna Stock Pops After Inking $950 Million Covid Vaccine Settlement [Yahoo! Finance]
3/4
09:22 am
abus
Moderna gains as Arbutus/ Genevant settlement removes major financial risk [Seeking Alpha]
Medium
Report
Moderna gains as Arbutus/ Genevant settlement removes major financial risk [Seeking Alpha]
3/4
09:21 am
abus
Moderna shares jump as settlement removes major legal overhang [Yahoo! Finance]
Low
Report
Moderna shares jump as settlement removes major legal overhang [Yahoo! Finance]
3/3
04:15 pm
abus
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
High
Report
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
2/3
08:00 am
abus
Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts [Seeking Alpha]
Medium
Report
Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts [Seeking Alpha]
1/23
05:06 am
abus
Arbutus Biopharma (NASDAQ:ABUS) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
Arbutus Biopharma (NASDAQ:ABUS) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Date
Time
Symbol
Company Name
Action
%Chg
8/6/2025
07:30 am
ABUS
arbutus biopharma corporation
BEAT
Report
0.6%
arbutus biopharma corporation
5/14/2025
07:30 am
ABUS
arbutus biopharma corporation
MISS
Report
-4.0%
arbutus biopharma corporation
3/28/2025
10:51 pm
ABUS
arbutus biopharma corporation
MISS
Report
0.9%
arbutus biopharma corporation
3/28/2025
10:35 pm
ABUS
arbutus biopharma corporation
MISS
Report
0.9%
arbutus biopharma corporation
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/3
04:21 pm
abus
Form 8-K Arbutus Biopharma Corp For: Mar 03
High
Report
Form 8-K Arbutus Biopharma Corp For: Mar 03
2/20
04:02 pm
abus
Form 8-K Arbutus Biopharma Corp For: Feb 17
Low
Report
Form 8-K Arbutus Biopharma Corp For: Feb 17
2/17
04:21 pm
abus
Form SCHEDULE 13G/A Arbutus Biopharma Corp Filed by: Two Seas Capital LP
Low
Report
Form SCHEDULE 13G/A Arbutus Biopharma Corp Filed by: Two Seas Capital LP
2/11
01:46 pm
abus
Form SCHEDULE 13G/A Arbutus Biopharma Corp Filed by: MORGAN STANLEY
Low
Report
Form SCHEDULE 13G/A Arbutus Biopharma Corp Filed by: MORGAN STANLEY
2/6
04:02 pm
abus
Form 8-K Arbutus Biopharma Corp For: Feb 02
Medium
Report
Form 8-K Arbutus Biopharma Corp For: Feb 02
2/2
08:22 pm
abus
Form 4 Arbutus Biopharma Corp For: Feb 02 Filed by: Nguyen Tuan
Medium
Report
Form 4 Arbutus Biopharma Corp For: Feb 02 Filed by: Nguyen Tuan
2/2
08:21 pm
abus
Form 4 Arbutus Biopharma Corp For: Feb 02 Filed by: Androski Lindsay
Medium
Report
Form 4 Arbutus Biopharma Corp For: Feb 02 Filed by: Androski Lindsay
1/16
07:42 am
abus
Form 8-K Arbutus Biopharma Corp For: Jan 15
High
Report
Form 8-K Arbutus Biopharma Corp For: Jan 15
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/20
Arbutus receives clearance to initiate early-stage AB-729 trial; shares up 8% premarket [Seeking Alpha]
32.6%
6/17 Arbutus Appoints William Collier as Next President & CEO and Announces Retirement of Current President & CEO, Mark J. Murray Ph.D. 24.7%
2/10 Arbutus Announces Decision to Discontinue AB-452 and to Pursue Development of a Next Generation HBV Specific Oral RNA-Destabilizer 20.6%
10/4 Arbutus Biopharma Corp (NASDAQ: ABUS) was downgraded by analysts at Chardan Capital from a "buy" rating to a "neutral" rating. 13.3%
2/27 Arbutus to Report Fourth Quarter and Year-End 2019 Financial Results 10.7%
11/4 We're A Little Worried About Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate [Yahoo! Finance News] 5.1%
5/20 Form 8-K Arbutus Biopharma Corp For: May 20 4.9%
7/3 Form 8-K Arbutus Biopharma Corp For: Jul 02 4.2%
7/12 Form 4 Arbutus Biopharma Corp For: Jul 10 Filed by: SVF Holdings (UK) LLP 4.0%
8/5 Arbutus Biopharma Corporation (ABUS) CEO William Collier on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 3.1%
6/17 Arbutus Appoints William Collier as Next President & CEO and Announces Retirement of Current President & CEO, Mark J. Murray Ph.D. 24.7%
2/10 Arbutus Announces Decision to Discontinue AB-452 and to Pursue Development of a Next Generation HBV Specific Oral RNA-Destabilizer 20.6%
10/4 Arbutus Biopharma Corp (NASDAQ: ABUS) was downgraded by analysts at Chardan Capital from a "buy" rating to a "neutral" rating. 13.3%
2/27 Arbutus to Report Fourth Quarter and Year-End 2019 Financial Results 10.7%
11/4 We're A Little Worried About Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate [Yahoo! Finance News] 5.1%
5/20 Form 8-K Arbutus Biopharma Corp For: May 20 4.9%
7/3 Form 8-K Arbutus Biopharma Corp For: Jul 02 4.2%
7/12 Form 4 Arbutus Biopharma Corp For: Jul 10 Filed by: SVF Holdings (UK) LLP 4.0%
8/5 Arbutus Biopharma Corporation (ABUS) CEO William Collier on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 3.1%
TOP News Decliners
3/26
Form 8-K Arbutus Biopharma Corp For: Mar 26
-47.4%
10/3 Form 8-K Arbutus Biopharma Corp For: Oct 03 -28.7%
10/7 Arbutus Biopharma Corp (NASDAQ: ABUS) had its price target lowered by analysts at B. Riley from $7.00 to $3.00. They now have a "buy" rating on the stock. -16.0%
7/15 Arbutus up 3% after hours on encouraging data on HBV candidate AB-506 [Seeking Alpha] -12.5%
7/18 Form 8-K Arbutus Biopharma Corp For: Jul 15 -11.3%
8/9 Form 8-K Arbutus Biopharma Corp For: Aug 09 -8.5%
5/13 Arbutus to Present at Upcoming May 2019 Conferences -7.9%
3/6 Form 10-K/A Arbutus Biopharma Corp For: Dec 31 -7.1%
5/28 Form 8-K Arbutus Biopharma Corp For: May 22 -6.9%
9/26 Arbutus to Participate in Upcoming Investor Conferences -6.3%
10/3 Form 8-K Arbutus Biopharma Corp For: Oct 03 -28.7%
10/7 Arbutus Biopharma Corp (NASDAQ: ABUS) had its price target lowered by analysts at B. Riley from $7.00 to $3.00. They now have a "buy" rating on the stock. -16.0%
7/15 Arbutus up 3% after hours on encouraging data on HBV candidate AB-506 [Seeking Alpha] -12.5%
7/18 Form 8-K Arbutus Biopharma Corp For: Jul 15 -11.3%
8/9 Form 8-K Arbutus Biopharma Corp For: Aug 09 -8.5%
5/13 Arbutus to Present at Upcoming May 2019 Conferences -7.9%
3/6 Form 10-K/A Arbutus Biopharma Corp For: Dec 31 -7.1%
5/28 Form 8-K Arbutus Biopharma Corp For: May 22 -6.9%
9/26 Arbutus to Participate in Upcoming Investor Conferences -6.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: